Background: Ivermectin has received worldwide attention as a potential COVID-19 treatment
after showing antiviral activity against SARS-CoV-2 in vitro. However, the pharmacokinetic …

SARS-CoV-2, the causative agent of COVID-19, predominantly affects the respiratory tract.
As a consequence, it seems intuitive to develop antiviral agents capable of targeting the …

Pharmacokinetic limitations associated with oral ivermectin may limit its success as a
potential COVID-19 treatment based on in vitro experiments which demonstrate antiviral …

Introduction SARS-CoV-2 replication in cell cultures has been shown to be inhibited by
ivermectin. However, ivermectin's low aqueous solubility and bioavailability hinders its …

Ivermectin is a widely used antiparasitic drug with known efficacy against several single-
strain RNA viruses. Recent data shows significant reduction of SARS-CoV-2 replication in …

In an effort to curb the global pandemic due to coronavirus, the scientific community is
exploring various treatment strategies with a special emphasis on drug repurposing …

Amid the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, the
search for effective treatment and vaccines has been exponentially on the rise. Finding …

Caly et al. 1 reported that ivermectin inhibited severe acute respiratory syndrome‐
coronavirus 2 (SARS‐CoV‐2) in vitro for up to 48 hours using ivermectin at 5 μM. The …

Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated
antiviral activity against a number of DNA and RNA viruses, including severe acute …

SARS-CoV-2 utilizes the IMPα/β1 heterodimer to enter host cell nuclei after gaining cellular
access through the ACE2 receptor. Ivermectin has shown antiviral activity by inhibiting the …